HENLIUS (02696) signed a cooperation agreement with Aohong Pharmaceutical on folic acid citrate capsules.

HENLIUS (02696) announced that on December 3, 2025, the company entered into a cooperation agreement with Aohong Pharmaceutical. According to this agreement, Aohong Pharmaceutical agreed to grant the group exclusive licensing rights to commercialize products in the region and field. The cooperation agreement was entered into after the two parties signed a memorandum of cooperation on August 7, 2025 (as a transaction that meets the minimum exemption level under the listing rules). The group has obtained exclusive commercialization rights in China for the licensed products during the transitional period until the date of formal signing of the cooperation agreement. The memorandum of cooperation has been replaced by the cooperation agreement and automatically terminated on December 3, 2025. The licensed product (Ribociclib Capsules) is a CDK4/6 inhibitor approved for the treatment of HR+, HER2- breast cancer. The licensed product aligns with the company's commercial layout in the field of breast cancer and has commercial synergies with the company's existing pipeline products for breast cancer. The introduction of the licensed product helps to enrich the company's pipeline and leverage the group's existing breast cancer commercialization team and resources to enhance the group's future revenue scale.